14,15-Epoxyeicosa-5(Z)-Enoic-mSI: A 14,15- and 5,6-EET antagonist in bovine coronary arteries

Hypertension

Volumn 42, Issue 4 I, 2003, Pages 555-561

  Gauthier, Kathryn M ^a   Jagadeesh, Setti G ^b   Falck, John R ^b   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acetylcholine; Arachidonic acids; Bradykinin; Endothelium derived factors; Vasodilation

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; ACETYLCHOLINE; ARACHIDONIC ACID; BIMAKALIM; BRADYKININ; CALCIUM ACTIVATED POTASSIUM CHANNEL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; ILOPROST; INDOMETACIN; METHACHOLINE; N(G) NITROARGININE; NITROPRUSSIDE SODIUM;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL REACTIVITY; CATTLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG STRUCTURE; KIDNEY MICROSOME; MASS SPECTROMETRY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; CATTLE; CORONARY VESSELS; CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; SULFONAMIDES; VASODILATOR AGENTS;

EID: 0141962643     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000091265.94045.C7     Document Type: Article

References (39)

1. Pinto A, Abraham NG, Mullane KM. Arachidonic acid-induced endothelial-dependent relaxation of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther. 1987;240: 856-863.
2. Campbell WB, Gebremehdin D, Pratt FP, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived relaxing factors. Circ Res. 1996;78:415-423.
3. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.
4. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994;481:407-414.
5. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992;107:722-725.
6. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106: 1521-1530.
7. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998; 396:269-272.
8. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Comm. 1996; 229:114-120.
9. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol. 2001;11:177-183.
10. Sandow SL, Hill CE. Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses. Circ Res. 2000;86:341-346.
11. Gauthier-Rein KM, Rusch NJ. Distinct endothelial impairment in coronary microvessels from hypertensive Dahl rats. Hypertension. 1998;31: 328-334.
12. Corriu C, Feletou M, Canet E, Vanhoutte PM. Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery. Br J Pharmacol. 1996; 117:607-610.
13. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Br J Pharmacol. 1997;120:439-446.
14. Vanheel B, Van de Voorde J. Evidence against the involvement of cytochrome P450 metabolites in endothelium-dependent hyperpolarization of the rat main mesenteric artery. J Physiol. 1997;501:331-341.
15. Van de Voorde J, Vanheel B. Influence of cytochrome P-450 inhibitors on endothelium-dependent nitro-L-arginine-resistant relaxation and cromakalim-induced relaxation in rat mesenteric arteries. J Cardiovasc Pharmacol. 1997;29:827-832.
16. + channels. Am J Physiol. 1997;273:C531-C540.
17. Rittenhouse AR, Vandorpe DH, Brugnara C, Alper SL. The antifungal imidazole clotrimazole and its major in vivo metabolite are potent blockers of the calcium-activated potassium channel in murine erythroleukemia cells. J Membr Biol. 1997;157:177-191.
18. Rittenhouse AR, Parker C, Brugnara C, Morgan KG, Alper SL. Inhibition of maxi-K currents in ferret portal vein smooth muscle cells by the antifungal clotrimazole. Am J Physiol. 1997;273:C45-C56.
19. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Deeter C, Gauthier KM, Campbell WB. Comparison of the vasodilatory properties of 14, 15-EET analogs: structural requirements for dilation. Am J Physiol. 2002;284:H337-H349.
20. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14, 15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90: 1028-1036.
21. Backes BJ, Ellman JA. Carbon-carbon bond-forming methods on solid support: utilization of Kenner's "safety-catch" linker. J Am Chem Soc. 1994;116:11171-11172.
22. Fang X, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11, 12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res. 1996;79:784-793.
23. Fang X, VanRollins M, Kaduce TL, Spector AA. Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. Circ Res. 1996;79: 784-793.
24. Snyder GD, Krishna UM, Falck JR, Spector AA. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol. 2002;283:H1936-H1942.
25. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, Campbell WB. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem. 2001;298:327-336.
26. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997;80:877-884.
27. Ca channels. Am J Physiol. 2002;282:H1656-H1664.
28. Popp R, Bauersachs J, Hecker M, Fleming I, Busse R. A transferable, B-napthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol. 1996; 497:699-709.
29. Gebremedhin D, Harder DR, Pratt PF, Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J Vasc Res. 1998;35: 274-284.
30. + channels in porcine coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 1998;32: 642-649.
31. Fulton D, Mahboubi K, McGiff JC, Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol. 1995; 114:99-102.
32. Gebremedhin D, Ma Y-H, Falck JR, Roman RJ, VanRollins M, Harder DR. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial muscle. Am J Physiol. 1992;263:H519-H525.
33. Nithipatikom K, Pratt FR, Campbell WB. Determination of EETs using microbore liquid chromatography with fluorescence detection. Am J Physiol. 2000;279:H857-H862.
34. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol. 1999;277: H2098-H2108.
35. +-channel activity. Am J Physiol. 1996;270: F822-F832.
36. Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC. Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol. 1987;138: 281-283.
37. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997;81:258-267.
38. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130: 963-974.
39. Shimokawa H. Endothelial function in hypertension. J Atheroscler Thomb. 1998;4:118-127.